NadA, a novel vaccine candidate of Neisseria meningitidis.
NadA, a novel vaccine candidate of Neisseria meningitidis.
复制标题
纳达（Nada），奈瑟氏菌脑膜炎的新型疫苗候选者。
DOI：
10.1084/jem.20020407
复制
发表时间：
2002-06-03
影响因子：
15.3
通讯作者：
Mora, Marirosa
中科院分区：
文献类型：
--
作者：
Comanducci, Maurizio;Bambini, Stefania;Brunelli, Brunella;Adu-Bobie, Jeannette;Arico, Beatrice;Capecchi, Barbara;Giuliani, Marzia Monica;Masignani, Vega;Santini, Laura;Savino, Silvana;Granoff, Dan M;Caugant, Dominique A;Pizza, Mariagrazia;Rappuoli, Rino;Mora, Marirosa
脑膜炎奈瑟菌是一种人类病原体，尽管有抗生素治疗，但它仍然是败血症和脑膜炎导致死亡的主要原因。在这里，我们描述了NadA，一种新的N.脑膜炎病毒存在于53株高毒力谱系电泳型（ET）ET 37、ET 5和簇A4中的52株中。该基因在超毒力谱系III中缺失，在N.淋球菌（G. lactamica和N.灰叶鸟嘌呤/胞嘧啶含量低于染色体，表明通过水平基因转移和随后的有限进化获得三个保守的等位基因。NadA具有预测的分子结构惊人地类似于一类新的粘附素（YadA和UspA 2），形成高分子量的寡聚体，并在体外结合上皮细胞，支持NadA对宿主细胞相互作用很重要的假设。NadA诱导强烈的杀菌抗体，并在婴儿大鼠模型中具有保护性，这表明这种蛋白质可能代表一种新的抗原，用于能够控制由三种高毒力谱系引起的脑膜炎球菌疾病的疫苗。
Neisseria meningitidis is a human pathogen, which, in spite of antibiotic therapy, is still a major cause of mortality due to sepsis and meningitis. Here we describe NadA, a novel surface antigen of N. meningitidis that is present in 52 out of 53 strains of hypervirulent lineages electrophoretic types (ET) ET37, ET5, and cluster A4. The gene is absent in the hypervirulent lineage III, in N. gonorrhoeae and in the commensal species N. lactamica and N. cinerea. The guanine/cytosine content, lower than the chromosome, suggests acquisition by horizontal gene transfer and subsequent limited evolution to generate three well-conserved alleles. NadA has a predicted molecular structure strikingly similar to a novel class of adhesins (YadA and UspA2), forms high molecular weight oligomers, and binds to epithelial cells in vitro supporting the hypothesis that NadA is important for host cell interaction. NadA induces strong bactericidal antibodies and is protective in the infant rat model suggesting that this protein may represent a novel antigen for a vaccine able to control meningococcal disease caused by three hypervirulent lineages.